心血管

订阅

MedSci主页 / 所有栏目 / 心血管

ATVB：循环白细胞介素1受体拮抗剂和心血管疾病风险有何关系？

2017-04-22 MedSci MedSci原创

IL-1β
关注

白细胞介素（IL）-1β是心血管疾病（CVD）发展的关键细胞因子。IL-1β受到了IL-1受体拮抗剂（IL-1RA）的调节，IL-1RA是一种内源性抑制剂。近日，心血管领域权威杂志Arteriosclerosis, Thrombosis, and Vascular Biology上发表了一篇研究文章，研究人员旨在通过系统评价确定以人群为基础的有关循环中IL-1RA和CVD事件的研究，通过荟萃分析来

白细胞介素（IL）-1β是心血管疾病（CVD）发展的关键细胞因子。IL-1β受到了IL-1受体拮抗剂（IL-1RA）的调节，IL-1RA是一种内源性抑制剂。近日，心血管领域权威杂志Arteriosclerosis, Thrombosis, and Vascular Biology上发表了一篇研究文章，研究人员旨在通过系统评价确定以人群为基础的有关循环中IL-1RA和CVD事件的研究，通过荟萃分析来估计IL-1RA和心血管事件之间的相关性，并通过MONICA/KORA奥格斯堡病例队列研究（奥格斯堡地区的心血管疾病/合作健康研究的趋势和决定因素的多国监测）来检验IL-1RA和CVD事件之间的相关性是否可以由其他炎症相关的生物标志物来进行解释。

研究人员进行了系统地文献搜索，并且确定了5个研究IL-1RA和CVD事件的队列研究，加上MONICA/KORA奥格斯堡病例队列研究进行荟萃分析，其是在共有1855名CVD患者和18745名非心血管疾病患者的基础上进行的，研究人员对这些患者共随访了5至16年。

在调整了年龄、性别、人体测量、代谢和生活方式因素后，该分析发生CVD合并的标准化风险比（95%可信区间）为1.11（1.06-1.17）（P＜0.0001）。效应大小没有异质性（I2=0%，P=0.88）。在MONICA/KORA研究中更详细的分析表明CVD的过度风险明显减弱了≥10%，在对血清高敏C-反应蛋白、IL-6、髓过氧化物酶、可溶性E-选择素水平或可溶性细胞间粘附分子-1进行单独的调整后。

由此可见，在6个以人群为基础的队列研究的荟萃分析中，对多种干扰因素进行调整后，血清IL-1RA水平与CVD风险呈正相关。这种相关性至少可以被所触发的反应部分地来反映，这些触发的反应包括亚临床炎症、氧化应激和内皮激活。

原始出处：

Christian Herder,et al.Circulating Levels of Interleukin 1-Receptor Antagonist and Risk of Cardiovascular Disease Meta-Analysis of Six Population-Based Cohorts.ATVB.2017. https://doi.org/10.1161/ATVBAHA.117.309307

本文系梅斯医学（MedSci）原创编译整理，转载需授权！


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (15)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1800093, encodeId=814818000936c, content=<a href='/topic/show?id=8665e17311b' target=_blank style='color:#2F92EE;'>#白细胞介素1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71731, encryptionId=8665e17311b, topicName=白细胞介素1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Oct 31 17:02:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977952, encodeId=2fe219e7952e8, content=<a href='/topic/show?id=20411e958de' target=_blank style='color:#2F92EE;'>#TVB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17958, encryptionId=20411e958de, topicName=TVB)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a5a149, createdName=gongliu, createdTime=Sat Jun 10 19:02:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190959, encodeId=b6d4190959ab, content=学习了谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Apr 27 06:20:43 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190334, encodeId=e35e19033485, content=认真学习，把间接经验应用到临床实践中去，然后再总结出新思路。给点赞啦……, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Apr 25 05:34:17 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473047, encodeId=353e14e304794, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Mon Apr 24 06:02:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498165, encodeId=2397149816516, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Apr 24 06:02:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511666, encodeId=5dc1151166648, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Mon Apr 24 06:02:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620549, encodeId=d4e3162054984, content=<a href='/topic/show?id=25a4e1714f0' target=_blank style='color:#2F92EE;'>#白细胞介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71714, encryptionId=25a4e1714f0, topicName=白细胞介素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1dc20143475, createdName=yxch43, createdTime=Mon Apr 24 06:02:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189811, encodeId=a6bc1898116f, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74221626377, createdName=tofsw, createdTime=Sun Apr 23 07:48:57 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189758, encodeId=a40a189e5814, content=不错，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2041447, createdName=1881e9c2b1m, createdTime=Sun Apr 23 01:38:19 CST 2017, time=2017-04-23, status=1, ipAttribution=)]
    2017-10-31 hb2008ye

    #白细胞介素1#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1800093, encodeId=814818000936c, content=<a href='/topic/show?id=8665e17311b' target=_blank style='color:#2F92EE;'>#白细胞介素1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71731, encryptionId=8665e17311b, topicName=白细胞介素1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Oct 31 17:02:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977952, encodeId=2fe219e7952e8, content=<a href='/topic/show?id=20411e958de' target=_blank style='color:#2F92EE;'>#TVB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17958, encryptionId=20411e958de, topicName=TVB)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a5a149, createdName=gongliu, createdTime=Sat Jun 10 19:02:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190959, encodeId=b6d4190959ab, content=学习了谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Apr 27 06:20:43 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190334, encodeId=e35e19033485, content=认真学习，把间接经验应用到临床实践中去，然后再总结出新思路。给点赞啦……, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Apr 25 05:34:17 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473047, encodeId=353e14e304794, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Mon Apr 24 06:02:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498165, encodeId=2397149816516, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Apr 24 06:02:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511666, encodeId=5dc1151166648, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Mon Apr 24 06:02:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620549, encodeId=d4e3162054984, content=<a href='/topic/show?id=25a4e1714f0' target=_blank style='color:#2F92EE;'>#白细胞介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71714, encryptionId=25a4e1714f0, topicName=白细胞介素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1dc20143475, createdName=yxch43, createdTime=Mon Apr 24 06:02:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189811, encodeId=a6bc1898116f, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74221626377, createdName=tofsw, createdTime=Sun Apr 23 07:48:57 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189758, encodeId=a40a189e5814, content=不错，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2041447, createdName=1881e9c2b1m, createdTime=Sun Apr 23 01:38:19 CST 2017, time=2017-04-23, status=1, ipAttribution=)]
    2017-06-10 gongliu

    #TVB#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1800093, encodeId=814818000936c, content=<a href='/topic/show?id=8665e17311b' target=_blank style='color:#2F92EE;'>#白细胞介素1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71731, encryptionId=8665e17311b, topicName=白细胞介素1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Oct 31 17:02:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977952, encodeId=2fe219e7952e8, content=<a href='/topic/show?id=20411e958de' target=_blank style='color:#2F92EE;'>#TVB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17958, encryptionId=20411e958de, topicName=TVB)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a5a149, createdName=gongliu, createdTime=Sat Jun 10 19:02:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190959, encodeId=b6d4190959ab, content=学习了谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Apr 27 06:20:43 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190334, encodeId=e35e19033485, content=认真学习，把间接经验应用到临床实践中去，然后再总结出新思路。给点赞啦……, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Apr 25 05:34:17 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473047, encodeId=353e14e304794, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Mon Apr 24 06:02:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498165, encodeId=2397149816516, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Apr 24 06:02:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511666, encodeId=5dc1151166648, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Mon Apr 24 06:02:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620549, encodeId=d4e3162054984, content=<a href='/topic/show?id=25a4e1714f0' target=_blank style='color:#2F92EE;'>#白细胞介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71714, encryptionId=25a4e1714f0, topicName=白细胞介素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1dc20143475, createdName=yxch43, createdTime=Mon Apr 24 06:02:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189811, encodeId=a6bc1898116f, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74221626377, createdName=tofsw, createdTime=Sun Apr 23 07:48:57 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189758, encodeId=a40a189e5814, content=不错，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2041447, createdName=1881e9c2b1m, createdTime=Sun Apr 23 01:38:19 CST 2017, time=2017-04-23, status=1, ipAttribution=)]
    2017-04-27 大爰

    学习了谢谢分享！

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1800093, encodeId=814818000936c, content=<a href='/topic/show?id=8665e17311b' target=_blank style='color:#2F92EE;'>#白细胞介素1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71731, encryptionId=8665e17311b, topicName=白细胞介素1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Oct 31 17:02:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977952, encodeId=2fe219e7952e8, content=<a href='/topic/show?id=20411e958de' target=_blank style='color:#2F92EE;'>#TVB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17958, encryptionId=20411e958de, topicName=TVB)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a5a149, createdName=gongliu, createdTime=Sat Jun 10 19:02:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190959, encodeId=b6d4190959ab, content=学习了谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Apr 27 06:20:43 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190334, encodeId=e35e19033485, content=认真学习，把间接经验应用到临床实践中去，然后再总结出新思路。给点赞啦……, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Apr 25 05:34:17 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473047, encodeId=353e14e304794, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Mon Apr 24 06:02:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498165, encodeId=2397149816516, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Apr 24 06:02:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511666, encodeId=5dc1151166648, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Mon Apr 24 06:02:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620549, encodeId=d4e3162054984, content=<a href='/topic/show?id=25a4e1714f0' target=_blank style='color:#2F92EE;'>#白细胞介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71714, encryptionId=25a4e1714f0, topicName=白细胞介素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1dc20143475, createdName=yxch43, createdTime=Mon Apr 24 06:02:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189811, encodeId=a6bc1898116f, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74221626377, createdName=tofsw, createdTime=Sun Apr 23 07:48:57 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189758, encodeId=a40a189e5814, content=不错，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2041447, createdName=1881e9c2b1m, createdTime=Sun Apr 23 01:38:19 CST 2017, time=2017-04-23, status=1, ipAttribution=)]
    2017-04-25 ylzr123

    认真学习，把间接经验应用到临床实践中去，然后再总结出新思路。给点赞啦……

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1800093, encodeId=814818000936c, content=<a href='/topic/show?id=8665e17311b' target=_blank style='color:#2F92EE;'>#白细胞介素1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71731, encryptionId=8665e17311b, topicName=白细胞介素1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Oct 31 17:02:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977952, encodeId=2fe219e7952e8, content=<a href='/topic/show?id=20411e958de' target=_blank style='color:#2F92EE;'>#TVB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17958, encryptionId=20411e958de, topicName=TVB)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a5a149, createdName=gongliu, createdTime=Sat Jun 10 19:02:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190959, encodeId=b6d4190959ab, content=学习了谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Apr 27 06:20:43 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190334, encodeId=e35e19033485, content=认真学习，把间接经验应用到临床实践中去，然后再总结出新思路。给点赞啦……, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Apr 25 05:34:17 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473047, encodeId=353e14e304794, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Mon Apr 24 06:02:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498165, encodeId=2397149816516, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Apr 24 06:02:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511666, encodeId=5dc1151166648, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Mon Apr 24 06:02:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620549, encodeId=d4e3162054984, content=<a href='/topic/show?id=25a4e1714f0' target=_blank style='color:#2F92EE;'>#白细胞介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71714, encryptionId=25a4e1714f0, topicName=白细胞介素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1dc20143475, createdName=yxch43, createdTime=Mon Apr 24 06:02:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189811, encodeId=a6bc1898116f, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74221626377, createdName=tofsw, createdTime=Sun Apr 23 07:48:57 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189758, encodeId=a40a189e5814, content=不错，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2041447, createdName=1881e9c2b1m, createdTime=Sun Apr 23 01:38:19 CST 2017, time=2017-04-23, status=1, ipAttribution=)]
    2017-04-24 花花1368

    #疾病风险#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1800093, encodeId=814818000936c, content=<a href='/topic/show?id=8665e17311b' target=_blank style='color:#2F92EE;'>#白细胞介素1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71731, encryptionId=8665e17311b, topicName=白细胞介素1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Oct 31 17:02:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977952, encodeId=2fe219e7952e8, content=<a href='/topic/show?id=20411e958de' target=_blank style='color:#2F92EE;'>#TVB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17958, encryptionId=20411e958de, topicName=TVB)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a5a149, createdName=gongliu, createdTime=Sat Jun 10 19:02:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190959, encodeId=b6d4190959ab, content=学习了谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Apr 27 06:20:43 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190334, encodeId=e35e19033485, content=认真学习，把间接经验应用到临床实践中去，然后再总结出新思路。给点赞啦……, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Apr 25 05:34:17 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473047, encodeId=353e14e304794, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Mon Apr 24 06:02:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498165, encodeId=2397149816516, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Apr 24 06:02:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511666, encodeId=5dc1151166648, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Mon Apr 24 06:02:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620549, encodeId=d4e3162054984, content=<a href='/topic/show?id=25a4e1714f0' target=_blank style='color:#2F92EE;'>#白细胞介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71714, encryptionId=25a4e1714f0, topicName=白细胞介素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1dc20143475, createdName=yxch43, createdTime=Mon Apr 24 06:02:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189811, encodeId=a6bc1898116f, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74221626377, createdName=tofsw, createdTime=Sun Apr 23 07:48:57 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189758, encodeId=a40a189e5814, content=不错，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2041447, createdName=1881e9c2b1m, createdTime=Sun Apr 23 01:38:19 CST 2017, time=2017-04-23, status=1, ipAttribution=)]
    2017-04-24 andy2090

    #血管疾病#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1800093, encodeId=814818000936c, content=<a href='/topic/show?id=8665e17311b' target=_blank style='color:#2F92EE;'>#白细胞介素1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71731, encryptionId=8665e17311b, topicName=白细胞介素1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Oct 31 17:02:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977952, encodeId=2fe219e7952e8, content=<a href='/topic/show?id=20411e958de' target=_blank style='color:#2F92EE;'>#TVB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17958, encryptionId=20411e958de, topicName=TVB)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a5a149, createdName=gongliu, createdTime=Sat Jun 10 19:02:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190959, encodeId=b6d4190959ab, content=学习了谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Apr 27 06:20:43 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190334, encodeId=e35e19033485, content=认真学习，把间接经验应用到临床实践中去，然后再总结出新思路。给点赞啦……, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Apr 25 05:34:17 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473047, encodeId=353e14e304794, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Mon Apr 24 06:02:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498165, encodeId=2397149816516, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Apr 24 06:02:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511666, encodeId=5dc1151166648, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Mon Apr 24 06:02:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620549, encodeId=d4e3162054984, content=<a href='/topic/show?id=25a4e1714f0' target=_blank style='color:#2F92EE;'>#白细胞介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71714, encryptionId=25a4e1714f0, topicName=白细胞介素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1dc20143475, createdName=yxch43, createdTime=Mon Apr 24 06:02:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189811, encodeId=a6bc1898116f, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74221626377, createdName=tofsw, createdTime=Sun Apr 23 07:48:57 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189758, encodeId=a40a189e5814, content=不错，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2041447, createdName=1881e9c2b1m, createdTime=Sun Apr 23 01:38:19 CST 2017, time=2017-04-23, status=1, ipAttribution=)]
    2017-04-24 ms5236388012055669

    #拮抗剂#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1800093, encodeId=814818000936c, content=<a href='/topic/show?id=8665e17311b' target=_blank style='color:#2F92EE;'>#白细胞介素1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71731, encryptionId=8665e17311b, topicName=白细胞介素1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Oct 31 17:02:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977952, encodeId=2fe219e7952e8, content=<a href='/topic/show?id=20411e958de' target=_blank style='color:#2F92EE;'>#TVB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17958, encryptionId=20411e958de, topicName=TVB)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a5a149, createdName=gongliu, createdTime=Sat Jun 10 19:02:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190959, encodeId=b6d4190959ab, content=学习了谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Apr 27 06:20:43 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190334, encodeId=e35e19033485, content=认真学习，把间接经验应用到临床实践中去，然后再总结出新思路。给点赞啦……, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Apr 25 05:34:17 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473047, encodeId=353e14e304794, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Mon Apr 24 06:02:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498165, encodeId=2397149816516, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Apr 24 06:02:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511666, encodeId=5dc1151166648, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Mon Apr 24 06:02:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620549, encodeId=d4e3162054984, content=<a href='/topic/show?id=25a4e1714f0' target=_blank style='color:#2F92EE;'>#白细胞介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71714, encryptionId=25a4e1714f0, topicName=白细胞介素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1dc20143475, createdName=yxch43, createdTime=Mon Apr 24 06:02:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189811, encodeId=a6bc1898116f, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74221626377, createdName=tofsw, createdTime=Sun Apr 23 07:48:57 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189758, encodeId=a40a189e5814, content=不错，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2041447, createdName=1881e9c2b1m, createdTime=Sun Apr 23 01:38:19 CST 2017, time=2017-04-23, status=1, ipAttribution=)]
    2017-04-24 yxch43

    #白细胞介素#

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1800093, encodeId=814818000936c, content=<a href='/topic/show?id=8665e17311b' target=_blank style='color:#2F92EE;'>#白细胞介素1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71731, encryptionId=8665e17311b, topicName=白细胞介素1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Oct 31 17:02:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977952, encodeId=2fe219e7952e8, content=<a href='/topic/show?id=20411e958de' target=_blank style='color:#2F92EE;'>#TVB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17958, encryptionId=20411e958de, topicName=TVB)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a5a149, createdName=gongliu, createdTime=Sat Jun 10 19:02:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190959, encodeId=b6d4190959ab, content=学习了谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Apr 27 06:20:43 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190334, encodeId=e35e19033485, content=认真学习，把间接经验应用到临床实践中去，然后再总结出新思路。给点赞啦……, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Apr 25 05:34:17 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473047, encodeId=353e14e304794, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Mon Apr 24 06:02:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498165, encodeId=2397149816516, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Apr 24 06:02:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511666, encodeId=5dc1151166648, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Mon Apr 24 06:02:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620549, encodeId=d4e3162054984, content=<a href='/topic/show?id=25a4e1714f0' target=_blank style='color:#2F92EE;'>#白细胞介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71714, encryptionId=25a4e1714f0, topicName=白细胞介素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1dc20143475, createdName=yxch43, createdTime=Mon Apr 24 06:02:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189811, encodeId=a6bc1898116f, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74221626377, createdName=tofsw, createdTime=Sun Apr 23 07:48:57 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189758, encodeId=a40a189e5814, content=不错，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2041447, createdName=1881e9c2b1m, createdTime=Sun Apr 23 01:38:19 CST 2017, time=2017-04-23, status=1, ipAttribution=)]
    2017-04-23 tofsw

    学习了谢谢分享

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1800093, encodeId=814818000936c, content=<a href='/topic/show?id=8665e17311b' target=_blank style='color:#2F92EE;'>#白细胞介素1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71731, encryptionId=8665e17311b, topicName=白细胞介素1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Oct 31 17:02:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977952, encodeId=2fe219e7952e8, content=<a href='/topic/show?id=20411e958de' target=_blank style='color:#2F92EE;'>#TVB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17958, encryptionId=20411e958de, topicName=TVB)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a5a149, createdName=gongliu, createdTime=Sat Jun 10 19:02:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190959, encodeId=b6d4190959ab, content=学习了谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Apr 27 06:20:43 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190334, encodeId=e35e19033485, content=认真学习，把间接经验应用到临床实践中去，然后再总结出新思路。给点赞啦……, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Apr 25 05:34:17 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473047, encodeId=353e14e304794, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Mon Apr 24 06:02:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498165, encodeId=2397149816516, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Apr 24 06:02:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511666, encodeId=5dc1151166648, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Mon Apr 24 06:02:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620549, encodeId=d4e3162054984, content=<a href='/topic/show?id=25a4e1714f0' target=_blank style='color:#2F92EE;'>#白细胞介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71714, encryptionId=25a4e1714f0, topicName=白细胞介素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1dc20143475, createdName=yxch43, createdTime=Mon Apr 24 06:02:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189811, encodeId=a6bc1898116f, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74221626377, createdName=tofsw, createdTime=Sun Apr 23 07:48:57 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189758, encodeId=a40a189e5814, content=不错，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2041447, createdName=1881e9c2b1m, createdTime=Sun Apr 23 01:38:19 CST 2017, time=2017-04-23, status=1, ipAttribution=)]
    2017-04-23 1881e9c2b1m

    不错，学习了

    0

以上为热门评论，梅斯医学App还有更多内容

相关资讯

Nature：挑战常规！半胱天冬酶-12并不作为炎性体的负调节物

炎性体（inflammasome）是细胞内的一类多蛋白复合物，在炎性反应中发挥着至关重要的作用。炎性体包括半胱天冬酶-1（caspase 1）、PYCARD和NALP，有时也包括半胱天冬酶-5（caspase 5，也被称作半胱天冬酶-11或ICH-3）。它是在骨髓细胞（myeloid cell）中产生的，也是先天性免疫系统的一个组分。炎性体的确切组成依赖于启动炎性体组装的激活物，如双链RNA和

Cell：范可尼贫血基因也在自噬和免疫中发挥功能

2016年5月3日/生物谷BIOON/--在一项新的研究中，来自美国德州大学西南医学中心（UTMC）、印第安纳大学医学院和三家欧洲科研机构的研究人员鉴定出范可尼贫血（Fanconi anemia, FA）途径中的基因的重要新功能，这一发现可能对开发用于治疗这种疾病和一些癌症的新疗法产生影响。相关研究结果于2016年4月28日在线发表在Cell期刊上，论文标题为“Fanconi Anemia

重磅！FDA一次性批准诺华抗炎药Ilaris 3个新的适应症

瑞士制药巨头诺华（Novartis）免疫管线近日在美国监管方面迎来重大喜讯。美国食品和药物管理局（FDA）已同时批准单抗药物Ilaris（canakimumab）3个新的适应症，用于治疗3种罕见和独特类型的周期性发热综合征：肿瘤坏死因子受体相关的周期性综合征（TRAPS）、高免疫球蛋白D综合征（HIDS）/甲羟戊酸激酶缺乏症（MKD）、家族性地中海热（FMF）。所有这3种疾病均属于名为周期性发